Related Articles
Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer
Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy
ADJUVANT CHEMOENDOCRINE THERAPY FOR EARLY BREAST-CANCER - IS IT WORTHWHILE - (REVIEW)
Survival outcome of combined GnRH agonist and tamoxifen is comparable to that of sequential adriamycin and cyclophosphamide chemotherapy plus tamoxifen in premenopausal patients with early breast cancer
Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine‑dependent breast cancer: A report of two cases